MARKET

STAB

STAB

Statera Biopharma Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.2399
-0.0021
-0.87%
After Hours: 0.2483 +0.0084 +3.50% 16:57 05/27 EDT
OPEN
0.2497
PREV CLOSE
0.2420
HIGH
0.2497
LOW
0.2253
VOLUME
979.86K
TURNOVER
0
52 WEEK HIGH
7.10
52 WEEK LOW
0.2019
MARKET CAP
12.00M
P/E (TTM)
-0.2526
1D
5D
1M
3M
1Y
5Y
Statera Biopharma receives letter from nasdaq regarding form 10-Q filing
Statera Biopharma (NASDAQ:STAB) said on Monday it had received a letter from the Nasdaq on May 18 stating that it had failed to file its quarterly report on form 10-Q
Seekingalpha · 4d ago
Statera Biopharma Receives Notification Letter From Nasdaq Regarding Form 10-Q Filing
  Statera Biopharma (NASDAQ:STAB) (the "Company"), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced the Company
Benzinga · 4d ago
Analyzing Statera BioPharma's Short Interest
Statera BioPharma's (NASDAQ:STAB) short percent of float has risen 287.8% since its last report. The company recently reported that it has 647.70 thousand shares sold short, which is 1.59% of all regular shares that are available for trading.
Benzinga · 05/17 15:13
Statera Biopharma stock rises on plans to license IgY products from Lay Sciences
Statera Biopharma (NASDAQ:STAB) plans to enter a strategic partnership to license global manufacturing rights to certain IgY products from Lay Sciences containing avian antibodies as an active ingredient. Under the proposed
Seekingalpha · 05/13 12:03
BRIEF-Statera Biopharma And Lay Sciences Inc Announce Intent To Enter Strategic Partnership To License The Manufacturing Rights To Certain Lay Sciences IgY Products
reuters.com · 05/13 11:42
Statera Biopharma Reports Strategic Partnership With Lay Sciences For License Of Manufacturing Rights To Certain Lay Sciences Products
Statera Biopharma (NASDAQ:STAB) (the “Company”), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced today that the Company
Benzinga · 05/13 11:32
Statera Biopharma and Lay Sciences Inc. Announce Intent to Enter Strategic Partnership to License the Manufacturing Rights to Certain Lay Sciences IgY Products
Statera expects to acquire option to license Lay Sciences products for respiratory & gastrointestinal disordersFORT COLLINS, Colo., May 13, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq: STAB) (the “Company”), a biopharmaceutical company creating next...
GlobeNewswire · 05/13 11:30
Top Premarket Gainers
MT Newswires · 05/13 08:20
More
No Data
Learn about the latest financial forecast of STAB. Analyze the recent business situations of Statera Biopharma Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
EPS
Actual
Estimate
-0.38-0.28-0.19-0.09
Q3 2020
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Institutional Holdings
Institutions: 36
Institutional Holdings: 2.12M
% Owned: 4.25%
Shares Outstanding: 50.02M
TypeInstitutionsShares
Increased
6
365.40K
New
11
667.88K
Decreased
6
380.76K
Sold Out
7
557.66K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
President/Chief Executive Officer/Director
Michael Handley
Chief Financial Officer
Peter Aronstam
Chief Operating Officer/Director
Taunia Markvicka
Chief Technology Officer
Robert Buckheit
Vice President - Finance
Christopher Zosh
Other
Clifford Selsky
Independent Director
Satish Chandran
No Data
No Data
About STAB
Statera BioPharma, Inc., formerly Cytocom, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing immunotherapies targeting autoimmune, neutropenia/anemia, viruses and cancers. Its Advanced Immunomodulating Multi-component System (AIMS) platform is designed to rebalance the body's immune system and restore homeostasis. Its platforms of toll-like receptor (TLR) agonists include TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532. Through its AIMS platform, the Company develops product candidates, which include STAT-200, STAT-400 and STAT-600 AIMS programs. Its STAT-200 program includes STAT-201, STAT-205, STAT-203 and STAT-202. STAT-201 is focused the treatment of Crohn’s disease. STAT-205 is focused on treatment of acute and post-acute coronavirus (COVID 19). Its STAT-400 programs include STAT-401 and STAT-400. STAT-401 is an injectable pentapeptide that is targeted for patients with pancreatic cancer.

Webull offers kinds of Statera Biopharma Inc stock information, including NASDAQ:STAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, STAB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading STAB stock methods without spending real money on the virtual paper trading platform.